Controlled inhalation of thin air may alleviate Parkinson's symptoms

Breathing thin air, akin to the air found at high mountain altitudes, typically strains the body. However, a study conducted at São Paulo State University in Brazil has revealed that brief, controlled exposure to low-oxygen air is safe and does not disrupt sleep. This controlled low-oxygen exposure can also influence hormones and markers related to inflammation in individuals with Parkinson's disease.

These early findings open avenues for further research into using this technique as a supplementary therapy for the condition. Known scientifically as intermittent hypoxia, this method aims to stimulate the body's adaptive responses without overwhelming it. The research, led by Fabio Barbieri, coordinator of the Human Movement Research Laboratory and the Ativa Parkinson outreach project at UNESP in Bauru, aimed to assess the potential benefits of intermittent hypoxia for people with Parkinson's disease.

Parkinson's disease, affecting an estimated 11 million people worldwide, is characterized by the progressive degeneration of dopamine-producing neurons, leading to motor symptoms such as tremors and muscle rigidity, as well as nonmotor manifestations like metabolic changes, inflammation, and sleep disorders. While medications manage the disease, they do not address metabolic and anti-inflammatory changes necessary to alleviate all symptoms.

Physical exercise is the sole current strategy to improve clinical manifestations, making it worth investigating whether controlled hypoxia could have a similar effect as a complementary treatment to physical exercise. The study, published in August in the journal Parkinsonism & Related Disorders, included 30 volunteers—half with Parkinson's disease and half healthy.

During a 39-minute experiment, the volunteers alternated between four six-minute cycles of breathing air with a 10% oxygen concentration (equivalent to an altitude of 5,800 meters) and three five-minute intervals of normal air (21% oxygen). On a separate day, as a control, they breathed only normal air. The researchers observed that a single session of intermittent hypoxia temporarily reduced cortisol and leptin levels in Parkinson's disease patients.

Cortisol is a stress hormone, and leptin, produced by adipose tissue, regulates metabolism and satiety. Excess leptin promotes inflammation, and its imbalance is often linked to brain inflammation, hormonal imbalances, and sleep problems in Parkinson's disease. The imbalance in cortisol, leptin, and adiponectin, which has anti-inflammatory effects, is often associated with these issues.

Therefore, the study demonstrates that intermittent hypoxia can modulate metabolism, potentially benefiting sleep behavior in Parkinson's disease patients. The researchers initially suspected hypoxia might cause awakenings or insomnia, but the experiment showed no such effects. A single session of intermittent hypoxia did not alter general sleep parameters, either in Parkinson's disease patients or healthy controls.

While a single session of the protocol modified blood biomarkers, such as reducing cortisol and increasing adiponectin, it may not fully reorganize the sleep-wake cycle. More in-depth and longer-term studies are needed to confirm these effects. The study also confirmed that the procedure did not alter blood iron levels or increase inflammatory molecules like interleukin-6, further supporting its safety.

Maintaining stable BDNF (brain-derived neurotrophic factor) levels, essential for neuron protection and survival, is a significant finding, as BDNF typically declines with physical inactivity. Intermittent hypoxia prevented this decline while increasing adiponectin, paving the way for further research into this therapy's potential benefits for Parkinson's disease.